Effects of long-term amiodarone treatment on ventricular-fibrillation vulnerability and defibrillation efficacy in response to monophasic and biphasic shocks

Journal of Cardiovascular Pharmacology

Volumn 30, Issue 4, 1997, Pages 412-418

  Behrens, Steffen ^a,b,c,d   Li, Cuilan ^a,b,c   Franz, Michael R ^a,b,c  

^a Division of Cardiology   (Germany)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Amiodarone; Defibrillation threshold; T wave shock; Upper limit of vulnerability; Ventricular fibrillation; Vulnerable window

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DEFIBRILLATION; DOSE RESPONSE; DRUG TISSUE LEVEL; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ELECTRIC COUNTERSHOCK; HEART FUNCTION TESTS; MALE; RABBITS; VENTRICULAR FIBRILLATION;

EID: 0030657558     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199710000-00002     Document Type: Article

References (56)

1. Powell AC, Fuchs P, Finkelstein DM, et al. Influence of the automatic implantable cardioverter-defibrillator on the long-terra prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88:1083-92.
2. Fogoros RN, Elson JJ, Bonnet CA, Fiedler SB, Burkholder JA. Efficacy of the automatic implantable cardioverter-defibrilllator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol 1990;16:381-6.
3. Neuzner J, for the European Ventak P2 Investigator Group. Clinical experience with a new cardioverter defibrillator capable of biphasic waveform pulse and enhanced data storage: results of a prospective multicenter study. PACE Pacing Clin Electrophysiol 1994;17:1243-55.
4. Manz M, Jung W, Lüderitz B, Interactions between drugs and devices: experimental and clinical studies. Am Heart J 1994; 127: 978-84.
5. Gottlieb CD, Horowitz LN. Potential interactions between antiarrhythmic medication and the automatic implantable cardioverter defibrillator. PACE Pacing Clin Electrophysiol 1991;14:898-904.
6. Steinhaus DM, Lemery R, Cardinal D, Foley L, Lipke J, Waters M. Implantable cardioverter defibrillators: long-term mortality revisited [Abstract]. Circulation 1995;92:I-783.
7. Li H, Axtell K, Biehl M, et al. Sudden death in patients with implantable cardioverter-defibrillators (ICD) [Abstract]. Circulation 1995;92:I783-4.
8. The CAST (Cardiac Arrhythmia Suppression Trial) Investigators. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
9. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
10. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortmann GR, Curiel R. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
11. Dolack GL. Clinical predictors of implantable cardioverter-defibrillator shocks (results of CASCADE Trial): cardiac arrest in Seattle, conventional versus amiodarone drug evaluation. Am J Cardiol 1994;73:237-41.
12. Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation 1983;68:88-94.
13. Fogoros RN. Amiodarone-induced refractoriness to cardioversion. Ann Intern Med 1984; 100:699-700.
14. Jung W, Manz M, Pizzulli L, Pfeiffer D, Lüderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992;70:1023-7.
15. Troup PJ, Chapman PD, Olinger GN, Kleinman LH. The implanted defibrillator: relation of defibrillating lead configuration and clinical variables to defibrillation threshold. J Am Coll Cardiol 1985;6:1315-21.
16. Guamieri T, Levine JH, Veltri EP, et al. Success of chronic defibrillation and the role of antiarrhythmic drugs with the automatic implantable cardioverter/defibrillator. Am J Cardiol 1987;60:1061-4.
17. Huang SK, Tan de Guzman WL, Chenarides JG, Okike NO, Vander Salm TJ. Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator. Am Heart J 1991; 122:720-7.
18. Bernstein RC, Raymond LJ, Onufer JR, et al. Factors influencing biphasic ED80 defibrillation threshold determination [Abstract]. PACE Pacing Clin Electrophysiol 1995;18:872.
19. Fain ES, Lee JT, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J 1987;114:8-17.
20. Haberman RJ, Veltri EP, Mower M. The effect of amiodarone on defibrillation threshold. J Electropliysiol 1988;2:415-23.
21. Frame LH. The effect of chronic oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs. PACE Pacing Clin Electrophysiol 1989;12:339-46.
22. Chen PS, Shibata N, Dixon EG, Martin RO, Ideker RE. Comparison of the defibrillation threshold and the upper limit of ventricular vulnerability. Circulation 1986;73:1022-8.
23. Chen PS, Feld GK, Kriett JM, et al. Relation between upper limit of vulnerability and defibrillation threshold in humans. Circulation 1993;88:186-92.
24. Souza JJ, Malkin RA, Ideker RE. Comparison of upper limit if vulnerability and defibrillation probability of success curves using a nonthoracotomy lead system. Circulation 1995;91:1247-52.
25. Malkin RA, Idriss SF, Walker RE, Ideker RE. Effect of rapid pacing and T-wave scanning on the relation between the defibrillation and upper-limit-of-vulnerability dose-response curves. Circulation 1995:92:1291-9.
26. Hwang C, Swerdlow C, Kass R, et al. Upper limit of vulnerability reliably predicts the defibrillation threshold in humans. Circulation 1994;90:2308-14.
27. Behrens S, Li C, Kirchhof P, Fabritz FL, Franz MR. Reduced arrhythmogenicity of biphasic versus monophasic T wave shocks: implications for defibrillation efficacy. Circulation 1996; 94:1974-80.
28. Kopp D, Kali J, Kinder C, Glascock D, Wilber D. Effect of amiodarone and left ventricular mass on deflbrillation energy requirements: monophasic vs. biphasic shocks [Abstract]. PACE Pacing Clin Electropliysiol 1995;18:305.
29. Franz MR, Cima R, Wang D, Profitt D, Kurz R. Electrophysiological effects of myocardial stretch and mechanical determinants of stretch-activated arrhythmias [published erratum in Circulation 1992;86:1663]. Circulation 1992;86:968-78.
30. Fabritz CL, Kirchhof PF, Behrens S, Zabel M, Franz MR. Myocardial vulnerability to T wave shocks: relation to shock strength, shock coupling interval, and dispersion of ventricular repolarization. J Cardiovasc Electrophysiol 1996;7:231-42.
31. Jones DL, Klein GJ, Gulamhusein S, Jarvis E. The repetitive ventricular response: relationship to ventricular fibrillation threshold in dogs. PACE Pacing Clin Electrophysiol 1983;6:1258-67.
32. MacConaill M. Ventricular fibrillation thresholds in Langendorff perfused rabbit hearts: all or none effect of low potassium concentration. J Cardiovasc Res 1987;21:463-8.
33. Merillat JC, Lakatta EG, Hano O, Guarnieri T. Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation. Circ Res 1990;67:1115-23.
34. McDaniel WC, Schuder JC. An up-down algorithm for estimation of the cardiac ventricular deflbrillation threshold. Med lustrum 1988;22:286-92.
35. Chen PS, Feld GK, Mower MM, Peters BB. Effects of pacing rate and timing of deflbrillation shock on the relation between the defibrillation threshold and the upper limit of vulnerability in open chest dogs. J Am Coll Cardiol 1991;18:1555-63.
36. Venkatesh N, Somani P, Bersohn M, Phair R, Kato R, Singh BN. Electropharmacology of amiodarone: absence of relationship to serum, myocardial, and cardiac sarcolemmal membrane drug concentrations. Am Heart J 1986;112:916-22.
37. Kodama I, Suzuki R, Kamiya K, Iwata H, Toyama J. Effects of long-term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle. Br J Pharmacol 1992;107:502-9.
38. Escoubet B, Jaillon P, Berger Y, et al. Amiodarone and N-desethylamiodarone concentrations in plasma, red blood cells, and myocardium after a single oral dose: relation to hemodynamic effects in surgical patients. Am Heart J 1986;111:280-5.
39. Anderson KP, Walker R, Dustman T, et al. Rate-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo. Circulation 1989;79: 948-58.
40. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J 1983;106:788-97.
41. Zabel M, Koller BS, Woosley RL, Hohnloser SH, Franz MR. Concentration-dependent effects of d-sotalol and amiodarone on dispersion of repolarization in the isolated intact rabbit heart [Abstract]. Eur Heart J 1995;16:436.
42. Cui G, Sen L, Sager P, Uppal P, Singh B. Effects of amiodarone, semaülide, and sotalol on QT dispersion. Am J Cardiol 1994;74:896-900.
43. Kirchhof PF, Fabritz CL, Zabel M, Franz MR. The vulnerable period for low and high energy T wave shocks: role of dispersion of repolarization and sotalol. Cardiovasc Res 1996;31:953-62.
44. Arredondo MT, Guillen SG, Quinteiro RA. Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischémie conditions. Eur J Pharmacol 1986;125:23-8.
45. Wellens HJJ, Brugada P, Abdollah H, Dassen WR. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation 1984;669:120-4.
46. Wharton JM, Wolf PD, Smith WM, et al. Cardiac potential and potential gradient fields generated by single, combined, and sequential shocks during ventricular defibrillation. Circulation 1992;85:1510-23.
47. Echt DS, Black JN, Barbey JT, Coxe DR, Cato E. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: sodium channel block and action potential prolongation. Circulation 1989;79:1106-17.
48. Wang M, Dorian P. DL and D sotalol decrease defibrillation energy requirements. PACE Pacing Clin Electrophysiol 1989; 12:1522-9.
49. Dorian P, Wang M, David I, Feindel C. Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model. Circulation 1991;83:614-21.
50. Fain ES, Dorian P, Davy JM, Kates RE, Winkle RA. Effects of encainide and its metabolites on energy requirements for defibrillation. Circulation 1986:73:1334-41.
51. Topham SL, Cha YM, Peters BB, Chen PS. Effects of lidocaine on relation between defibrillation threshold and upper limit of vulnerability in open-chest dogs. Circulation 1992;85:1146-51.
52. Ujhelyi MR, Schur M, Frede T, Bottorff MB, Gabel M, Markel ML. Mechanisms of antiarrhythmic drug-induced changes in defibrillation threshold: role of potassium and sodium channel conductance. JAm Coll Cardiol 1996;27:1534-42.
53. Brugada J, Boersma L, Kirchhof C, Allessie M. Proarrhythmic effects of flecainide: experimental evidence for increased susceptibility to reentrant arrhythmias. Circulation 1991;84:1808-18.
54. Swartz JF, Fletcher RD, Karasik PE. Optimization of biphasic waveforms for human nonthoracotomy defibrillation. Circulation 1993:88:2646-54.
55. Chen PS, Shibata N, Dixon EG, Martin RO, Ideker RE. Comparison of the defibrillation threshold and the upper limit of ventricular vulnerability. Circulation 1986;73:1022-8.
56. Wharton JM, Richard VJ, Murry CE, et al. Electrophysiological effects of monophasic and biphasic stimuli in normal and infarcted dogs. PACE Pacing Clin Electrophysiol 1990;13:1158-72.